CELLECTIS (ALCLS.PA) Stock Overview
Europe - EPA:ALCLS - FR0010425595 - Common Stock
ALCLS.PA Key Statistics, Chart & Performance
The current stock price of ALCLS.PA is 2.685 EUR. In the past month the price increased by 5.71%. In the past year, price increased by 29.71%.
ALCLS.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 20.69 | 330.35B | ||
| AMG.DE | AMGEN INC | 12.8 | 128.24B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.09 | 123.73B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 23.34 | 86.52B | ||
| 1VRTX.MI | VERTEX PHARMACEUTICALS INC | 23.04 | 85.81B | ||
| 1AE.DE | ARGENX SE | 87.46 | 39.45B | ||
| ARGX.BR | ARGENX SE | 87.44 | 39.44B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.45B | ||
| 1BIIB.MI | BIOGEN INC | 9.22 | 18.55B | ||
| IDP.DE | BIOGEN INC | 9.26 | 18.55B | ||
| 1EXEL.MI | EXELIXIS INC | 18.64 | 8.93B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.36B |
Related stock screener links
About ALCLS.PA
Company Profile
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Company Info
CELLECTIS
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE FR
Employees: 219
Phone: 33181691600
CELLECTIS / ALCLS.PA FAQ
What is the stock price of CELLECTIS today?
The current stock price of ALCLS.PA is 2.685 EUR. The price decreased by -3.76% in the last trading session.
What is the ticker symbol for CELLECTIS stock?
The exchange symbol of CELLECTIS is ALCLS and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ALCLS.PA stock listed?
ALCLS.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for CELLECTIS stock?
13 analysts have analysed ALCLS.PA and the average price target is 6.63 EUR. This implies a price increase of 146.93% is expected in the next year compared to the current price of 2.685. Check the CELLECTIS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CELLECTIS worth?
CELLECTIS (ALCLS.PA) has a market capitalization of 269.37M EUR. This makes ALCLS.PA a Micro Cap stock.
How many employees does CELLECTIS have?
CELLECTIS (ALCLS.PA) currently has 219 employees.
What are the support and resistance levels for CELLECTIS (ALCLS.PA) stock?
CELLECTIS (ALCLS.PA) has a support level at 2.39 and a resistance level at 2.79. Check the full technical report for a detailed analysis of ALCLS.PA support and resistance levels.
Is CELLECTIS (ALCLS.PA) expected to grow?
The Revenue of CELLECTIS (ALCLS.PA) is expected to decline by -3.47% in the next year. Check the estimates tab for more information on the ALCLS.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CELLECTIS (ALCLS.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALCLS.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALCLS.PA, evaluating the profitability, health, valuation and growth aspects
- CELLECTIS (ALCLS.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CELLECTIS (ALCLS.PA) Sales and EPS estimates to see what analysts future expectations are.
- CELLECTIS (ALCLS.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CELLECTIS (ALCLS.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CELLECTIS (ALCLS.PA) Stock Chart to make your own analysis
- CELLECTIS (ALCLS.PA) Latest news and press-releases to stay up to date.
Does CELLECTIS (ALCLS.PA) stock pay dividends?
ALCLS.PA does not pay a dividend.
When does CELLECTIS (ALCLS.PA) report earnings?
CELLECTIS (ALCLS.PA) will report earnings on 2025-11-03.
What is the Price/Earnings (PE) ratio of CELLECTIS (ALCLS.PA)?
CELLECTIS (ALCLS.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.49).
ALCLS.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALCLS.PA. When comparing the yearly performance of all stocks, ALCLS.PA is one of the better performing stocks in the market, outperforming 96.64% of all stocks.
ALCLS.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA. ALCLS.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALCLS.PA Financial Highlights
Over the last trailing twelve months ALCLS.PA reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS increased by 52.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.3% | ||
| ROE | -103.16% | ||
| Debt/Equity | 0.91 |
ALCLS.PA Forecast & Estimates
13 analysts have analysed ALCLS.PA and the average price target is 6.63 EUR. This implies a price increase of 146.93% is expected in the next year compared to the current price of 2.685.
For the next year, analysts expect an EPS growth of -213.93% and a revenue growth -3.47% for ALCLS.PA